Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 /
The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented.
Main Authors: | , |
---|---|
Format: | Texto biblioteca |
Language: | eng |
Published: |
Berlin, Heidelberg : Springer Berlin Heidelberg,
1989
|
Subjects: | Medicine., Pharmacology., General practice (Medicine)., Endocrinology., Gastroenterology., Hepatology., Pathology., Medicine & Public Health., General Practice / Family Medicine., Pharmacology/Toxicology., |
Online Access: | http://dx.doi.org/10.1007/978-3-642-61328-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
KOHA-OAI-TEST:198419 |
---|---|
record_format |
koha |
spelling |
KOHA-OAI-TEST:1984192018-07-30T23:25:05ZSandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / O’Dorisio, T. M. editor. SpringerLink (Online service) textBerlin, Heidelberg : Springer Berlin Heidelberg,1989.engThe secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented.1. Prologue -- 2. Chemical Structure — Pharmacological Profile of Sandostatin® -- 3. Carcinoid Tumours and the Carcinoid Syndrome -- 4. Tumors of the Gastroentero-pancreatic Axis -- 5. The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis -- 6. Sandostatin®: Assay and Efficacy in VIPoma and Insulinoma -- 7. Sandostatin® in Digestive Endocrine Tumors -- 8. VIPoma, Gastrinoma and Glucagonoma -- 9. Rebound Effect and Escape of Diarrhea Inhibition Using Sandostatin® in VIPoma Patients -- 10. Long-Term Treatment of VIPoma and Glucagonoma with Sandostatin® -- 111. Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma -- 12. Sandostatin® in the Treatment of Advanced Malignancies -- 13. Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with Sandostatin® -- 14. Sandostatin® and Gastroentero-pancreatic Endocrine Tumors -Therapeutic Characteristics -- 15. Consensus -- 16. Future Directions.The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented.Medicine.Pharmacology.General practice (Medicine).Endocrinology.Gastroenterology.Hepatology.Pathology.Medicine & Public Health.Hepatology.Gastroenterology.Endocrinology.General Practice / Family Medicine.Pharmacology/Toxicology.Pathology.Springer eBookshttp://dx.doi.org/10.1007/978-3-642-61328-9URN:ISBN:9783642613289 |
institution |
COLPOS |
collection |
Koha |
country |
México |
countrycode |
MX |
component |
Bibliográfico |
access |
En linea En linea |
databasecode |
cat-colpos |
tag |
biblioteca |
region |
America del Norte |
libraryname |
Departamento de documentación y biblioteca de COLPOS |
language |
eng |
topic |
Medicine. Pharmacology. General practice (Medicine). Endocrinology. Gastroenterology. Hepatology. Pathology. Medicine & Public Health. Hepatology. Gastroenterology. Endocrinology. General Practice / Family Medicine. Pharmacology/Toxicology. Pathology. Medicine. Pharmacology. General practice (Medicine). Endocrinology. Gastroenterology. Hepatology. Pathology. Medicine & Public Health. Hepatology. Gastroenterology. Endocrinology. General Practice / Family Medicine. Pharmacology/Toxicology. Pathology. |
spellingShingle |
Medicine. Pharmacology. General practice (Medicine). Endocrinology. Gastroenterology. Hepatology. Pathology. Medicine & Public Health. Hepatology. Gastroenterology. Endocrinology. General Practice / Family Medicine. Pharmacology/Toxicology. Pathology. Medicine. Pharmacology. General practice (Medicine). Endocrinology. Gastroenterology. Hepatology. Pathology. Medicine & Public Health. Hepatology. Gastroenterology. Endocrinology. General Practice / Family Medicine. Pharmacology/Toxicology. Pathology. O’Dorisio, T. M. editor. SpringerLink (Online service) Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / |
description |
The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented. |
format |
Texto |
topic_facet |
Medicine. Pharmacology. General practice (Medicine). Endocrinology. Gastroenterology. Hepatology. Pathology. Medicine & Public Health. Hepatology. Gastroenterology. Endocrinology. General Practice / Family Medicine. Pharmacology/Toxicology. Pathology. |
author |
O’Dorisio, T. M. editor. SpringerLink (Online service) |
author_facet |
O’Dorisio, T. M. editor. SpringerLink (Online service) |
author_sort |
O’Dorisio, T. M. editor. |
title |
Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / |
title_short |
Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / |
title_full |
Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / |
title_fullStr |
Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / |
title_full_unstemmed |
Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors [electronic resource] : Consensus Round Table, Scottsdale (Arizona), March 22, 1987 / |
title_sort |
sandostatin® in the treatment of gastroenteropancreatic endocrine tumors [electronic resource] : consensus round table, scottsdale (arizona), march 22, 1987 / |
publisher |
Berlin, Heidelberg : Springer Berlin Heidelberg, |
publishDate |
1989 |
url |
http://dx.doi.org/10.1007/978-3-642-61328-9 |
work_keys_str_mv |
AT odorisiotmeditor sandostatininthetreatmentofgastroenteropancreaticendocrinetumorselectronicresourceconsensusroundtablescottsdalearizonamarch221987 AT springerlinkonlineservice sandostatininthetreatmentofgastroenteropancreaticendocrinetumorselectronicresourceconsensusroundtablescottsdalearizonamarch221987 |
_version_ |
1756267151579152384 |